seekingalpha.com /3 days ago

FPA New Income Fund Q3 2026 Commentary

Read source
psychedelicalpha.com /3 weeks ago

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative...

Read source
seekingalpha.com /1 month ago

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Read source
newswire.com /1 month ago

NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals

Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections

Read source
seekingalpha.com /4 weeks ago

First National Non-GAAP EPS of $0.76 beats by $0.13, revenue of $25.29M beats by $1.02M

Read source
pharmexec.com /3 weeks ago

<![CDATA[Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fert...

Read source
seekingalpha.com /1 month ago

Nufarm Limited (NUFMF) Analyst/Investor Day - Slideshow

Read source
pharmexec.com /1 week ago

<![CDATA[Pharmaceutical Executive Daily: FDA Shelves CNPV Program]]>

Read source
orthospinenews.com /6 days ago

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…

Read source
pharmexec.com /2 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>

Read source
globalnews.ca /1 week ago

Neffy nasal spray for severe allergies now available without prescription

The National Association of Pharmacy Regulatory Authorities (NAPRA) classified Neffy as a Schedule II product across Canada, which means it can now be sold over the counter.

Read source
seekingalpha.com /1 month ago

NFJ's Tender Offer Results

Read source
kentucky.statenews.net /1 month ago

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

PRNewswireMumbai (Maharashtra) [India], October 1: Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal...

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
cafepharma.com /1 month ago

Kiniksa

Kiniksa Anonymous (not verified) Mon, 10/05/2026 - 04:07 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Read source
seekingalpha.com /1 month ago

Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow

Read source
genengnews.com /1 week ago

Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition

The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-a...

Read source
seekingalpha.com /1 week ago

Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans - Slideshow

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>

Read source
seekingalpha.com /1 month ago

PFO: Rate Pressures Present Better Entry Price For This Fund

Read source
seekingalpha.com /1 month ago

Lilly wins EU backing for Foundayo weight-loss pill

Read source
pharmexec.com /1 week ago

<![CDATA[Pfizer and Blackstone Sign Co-Funding Deal for berobenatide]]>

Read source
investing.com /1 month ago

Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.